About: Broad Protection of Pigs against Heterologous PRRSV Strains by a GP5-Mosaic DNA Vaccine Prime/GP5-Mosaic rVaccinia (VACV) Vaccine Boost

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Broad Protection of Pigs against Heterologous PRRSV Strains by a GP5-Mosaic DNA Vaccine Prime/GP5-Mosaic rVaccinia (VACV) Vaccine Boost Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Broad Protection of Pigs against Heterologous PRRSV Strains by a GP5-Mosaic DNA Vaccine Prime/GP5-Mosaic rVaccinia (VACV) Vaccine Boost
Creator	Garmendia, Antonio Cui, Junru Hagen, Connor Kruiningen, Herbert O'connell, Caitlin Sawicki, Kim Smyth, Joan Verardi, Paulo
source	PMC
abstract	Background: Porcine reproductive and respiratory syndrome (PRRS) viruses are a major cause of disease and economic loss in pigs worldwide. High genetic diversity among PRRSV strains is problematic for successful disease control by vaccination. Mosaic DNA and vaccinia (VACV) vaccines were developed in order to improve protection against heterologous PRRSV strains. Methods: Piglets were primed and boosted with GP5-Mosaic DNA vaccine and recombinant GP5-Mosaic VACV (rGP5-Mosaic VACV), respectively. Pigs vaccinated with rGP5-WT (VR2332) DNA and rGP5-WT VACV, or empty vector DNA and empty VACV respectively, served as controls. Virus challenge was given to separate groups of vaccinated pigs with VR2332 or MN184C. Necropsies were performed 14 days after challenge. Results: Vaccination with the GP5-Mosaic-based vaccines resulted in cellular reactivity and higher levels of neutralizing antibodies to both VR2332 and MN184C PRRSV strains. In contrast, vaccination of animals with the GP5-WT vaccines induced responses only to VR2332. Furthermore, vaccination with the GP5-Mosaic based vaccines resulted in protection against challenge with two heterologous virus strains, as demonstrated by the significantly lower viral loads in serum, tissues, porcine alveolar macrophages (PAMs), and bronchoalveolar lavage (BAL) fluids, and less severe lung lesions after challenge with either MN184C or VR2332, which have only 85% identity. In contrast, significant protection by the GP5-WT based vaccines was only achieved against the VR2332 strain. Conclusions: GP5-Mosaic vaccines, using a DNA-prime/VACV boost regimen, conferred protection in pigs against heterologous viruses.
has issue date	2020-02-28(xsd:dateTime)
bibo:doi	10.3390/vaccines8010106
bibo:pmid	32121277
has license	cc-by
sha1sum (hex)	1f7c4b6fc91f3143baa4824a7f8050f16d9bcccd
schema:url	https://doi.org/10.3390/vaccines8010106
resource representing a document's title	Broad Protection of Pigs against Heterologous PRRSV Strains by a GP5-Mosaic DNA Vaccine Prime/GP5-Mosaic rVaccinia (VACV) Vaccine Boost
has PubMed Central identifier	PMC7157218
has PubMed identifier	32121277
schema:publication	Vaccines (Basel)
resource representing a document's body	covid:1f7c4b6fc91f3143baa4824a7f8050f16d9bcccd#body_text
is schema:about of	named entity 'Virus' named entity 'Background' named entity 'fluids' named entity 'separate' named entity 'strains' named entity 'vaccinated' named entity 'heterologous' named entity 'vaccination' named entity 'levels' named entity 'Mosaic' named entity 'strains' named entity 'Prime' named entity 'PIGS' named entity 'PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME' named entity 'HETEROLOGOUS' covid:arg/1f7c4b6fc91f3143baa4824a7f8050f16d9bcccd named entity 'vaccines' named entity 'empty' named entity 'macrophages' named entity 'primed' named entity 'Mosaic' named entity 'control' named entity 'Necropsies' named entity 'boost' named entity 'PAMs' named entity 'viruses' named entity 'disease' named entity 'loss' named entity 'problematic' named entity 'vaccinated' named entity 'DNA vaccine' named entity 'lung' named entity 'serum' named entity 'Vaccine' named entity 'vector' named entity 'tonsils' named entity 'lung' named entity 'mRNA expression' named entity 'real-time PCR' named entity 'multiplicity of infection' named entity 'IPTG' named entity 'IFN-γ' named entity 'vector' named entity 'cancer immunotherapy' named entity 'virus' named entity 'tetR' named entity 'tonsil' named entity 'naturally occurring' named entity 'PBMC' named entity 'lung' named entity 'serum' named entity 'PBS' named entity 'gene' named entity 'lipid envelope' named entity 'PRRSV' named entity 'vector' named entity 'lung' named entity 'vector' named entity '0.01' named entity 'subunit vaccines' named entity 'RNA' named entity '85%' named entity 'Recombinant' named entity 'bacterial pathogens' named entity 'USDA-ARS' named entity 'Student's t test' named entity 'doxycycline' named entity 'vaccination' named entity 'lung' named entity 'mRNA' named entity '0.9' named entity 'vector' named entity 'lung' named entity 'PRRS'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software